Oncogenic Mutant <i>p53</i> Sensitizes Non–Small Cell Lung Cancer Cells to Proteasome Inhibition via Oxidative Stress–Dependent Induction of Mitochondrial Apoptosis
NSCLC is the leading cause of cancer death due, in part, to a lack of active therapies in advanced disease. We demonstrate that combination therapy with a proteasome inhibitor, BH3-mimetic, and chemotherapy is an active precision therapy in NSCLC cells and tumors expressing Onc-p53 alleles.
Authors
- Sumitra Deb
- Kranthi Kumar Chougoni (ORCID: https://orcid.org/0000-0003-4102-8723)
- Steven R. Grossman
- Bradford E. Windle (ORCID: https://orcid.org/0000-0001-9613-7084)
- Victoria Neely
- Eziafa Oduah (ORCID: https://orcid.org/0000-0001-8517-6360)
- Hisashi Harada (ORCID: https://orcid.org/0000-0001-5993-1289)
- Senthil K. Radhakrishnan (ORCID: https://orcid.org/0000-0002-5211-9498)
- Jorge J. Nieva (ORCID: https://orcid.org/0000-0003-1605-4719)
- Bin Hu (ORCID: https://orcid.org/0000-0003-3710-3786)
- Jennifer E. Koblinski (ORCID: https://orcid.org/0000-0002-7156-2030)
- Swati Palit Deb
- Boxiao Ding
- Vianna T. Lam
Institutions
- University of Southern California (US)
- Virginia Commonwealth University (US)
- Duke Medical Center (US)
- Duke Cancer Institute
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2024-09-20
- DOI
- https://doi.org/10.1158/2767-9764.crc-23-0637
- Citations
- 6
- Primary Topic
- Ubiquitin and proteasome pathways
- Type
- article
- Field-Weighted Citation Impact
- 1.40
Funders
- Virginia Commonwealth University
- USC Norris Comprehensive Cancer Center
- National Institutes of Health
- School of Pharmacy, University of Southern California
- VCU Massey Cancer Center
- National Cancer Institute